Vascular Closure Device Market Size & Share Analysis - Growth Trends And Forecast (2025 - 2030)

Global Vascular Closure Device Market Trends and Insights

Increase in Catheterization-Related Procedures

Procedure counts have escalated as indications for percutaneous coronary interventions, structural heart repair, and complex peripheral revascularization broaden. Abbott confirmed that vessel closure products were a key contributor to its 12.5% medical devices revenue growth in Q1 2025, reflecting direct linkage between access‐site volumes and device demand. Mechanical thrombectomy and high-sheath electrophysiology cases produce multiple puncture sites per patient, pushing operators toward closure systems that manage varied vessel sizes with consistent outcomes. Trials such as AMBULATE demonstrated a 54% reduction in time to ambulation when the VASCADE MVP system replaced manual compression, underscoring workflow gains^{[1]H. Patel et al., “AMBULATE Trial,” Journal of the American College of Cardiology, jacc.org}. Together, these dynamics position procedural volume growth as a persistent catalyst for the vascular closure devices market.

Growing Preference for Minimally Invasive Interventions

Hospitals and ambulatory centers favor minimally invasive care to trim length of stay, reduce infection risk, and improve patient satisfaction. The Heart Rhythm Society and the American College of Cardiology endorse same-day discharge after intracardiac ablation when secure venous hemostasis is achieved, directly tying closure performance to throughput. Terumo’s 15.6% revenue jump in its Cardiac & Vascular Company aligns with this macro-shift and illustrates how robust closure tools accelerate adoption of catheter-based therapies. Imaging navigation improvements further widen the scope of lesions treatable through small punctures, amplifying reliance on vascular closure devices market solutions that seal access quickly and predictably.

Aging Population Expanding Cardiovascular Treatment Volumes

By 2040, individuals ≥65 years will represent 22% of the population, raising the prevalence of structural heart disease and peripheral arterial disease. Elderly cohorts often require multi-site interventions and present coagulation challenges that favor device-based closure over prolonged manual pressure. Japan’s rapid uptake of percutaneous left atrial appendage occlusion after WATCHMAN approval illustrates how age-driven morbidity expands demand for vascular closure devices market products tailored to fragile vessels. Demographic pressure is long lasting and geographically universal, giving suppliers a durable growth runway.

Expansion of Large-Bore TAVR/EVAR Driving Next-Gen Device Demand

Large-bore arteriotomies from 10 Fr to 25 Fr are now commonplace in TAVR and EVAR. Teleflex’s MANTA device and the InSeal VCD both achieved favorable clinical results in closing up to 25 Fr punctures, addressing gaps left by legacy plug technologies. With the global TAVR procedure volume rising toward 300,000 annually, hospitals seek closure platforms that obviate surgical cut-down, shorten turnaround, and reduce bleeding events. Manufacturers with proven large-bore offerings therefore occupy a premium niche within the broader vascular closure devices market.

High Cost Of Advanced VCDs Versus Manual Compression

A single closure unit often prices between USD 200 and USD 250, contrasted with negligible material cost for manual compression. While high-income systems justify expenditure through staff time savings, many emerging markets still rely on manual pressure to contain budgets. Value-based purchasing is gradually shifting toward total episode economics, but capital scarcity keeps price sensitivity high, especially where catheter volumes are just now scaling. Manufacturers are responding with tiered product lines and targeted reimbursement dossiers that highlight reduced nursing hours and shorter admissions.

Device-Related Complications And Product Recalls

Safety events undermine physician confidence and trigger regulatory scrutiny. The FDA’s Class I recall of Medtronic’s Pipeline Vantage embolization platform in March 2025 involved 7,820 devices and reignited debate on deployment complexity^{[2]U.S. Food and Drug Administration, “Medical Device Recall: Pipeline Vantage,” fda.gov}. Philips also withdrew its Tack Endovascular System because of incomplete wall apposition concerns, reinforcing vigilance across neurovascular closure applications. Though serious adverse events are statistically rare, publicity around any Class I action can slow adoption curves. Continuous operator education, design refinements, and post-market surveillance are central to sustaining growth in the vascular closure devices market.

Segment Analysis

By Product Type: Active Approximators Remain the Workhorse

Active approximators controlled 54.34% of the vascular closure devices market in 2024. This leadership derives from their suture-mediated or clip-based mechanisms that lock arteriotomies immediately, enabling anticoagulated or large-bore patients to ambulate within hours. Abbott’s Perclose ProGlide illustrates category strength by offering 100% procedural success in multiple high-sheath trials. Hospitals prize the deterministic closure these devices provide, particularly when intra-procedural anticoagulation is mandatory.

Passive approximators occupy a smaller base but are pacing growth at 8.45% CAGR through 2030. Plug, patch, and sealant systems such as Haemonetics’ VASCADE MVP shorten deployment to a single push, reducing fluoroscopy and operator fatigue. The AMBULATE study confirmed a 54% decline in time-to-ambulation, showcasing workflow dividends that resonate with outpatient programs. Simplified technique lowers training barriers, raising adoption in mid-volume centers. As regulatory pressures favor same-day discharge, passive approximators are positioned to expand their contribution to the vascular closure devices market.

Note: Segment shares of all individual segments available upon report purchase

By Material Composition: Bio-Absorbable Polymers Challenge Collagen Dominance

Collagen plugs retained 51.23% share in 2024, reflecting three decades of clinical familiarity. Terumo’s Angio-Seal VIP employs a collagen sponge, a polymer anchor, and a suture that collectively resorb within 90 days, offering predictable vessel healing. Physicians value collagen’s thrombin-rich matrix, which accelerates clot formation especially in anticoagulated patients.

Suture and filament devices built from polyglycolic acid, polyethylene glycol, or proprietary polymers are advancing at 8.95% CAGR. Vivasure’s PerQseal Elite is entirely bio-absorbable and designed for 14-22 Fr TAVR sheaths, eliminating retained foreign material and imaging artifacts. Polymer innovations provide tailored degradation kinetics, enabling large-bore security without permanent implants. Clip-based metal systems remain a niche for cases where radiopaque markers aid follow-up imaging. Material diversification reinforces competitive differentiation inside the vascular closure devices market.

By Mode of Access: Large-Bore Innovation Steals the Spotlight

Femoral access ≤8 Fr continues to dominate with 61.45% of vascular closure devices market size in 2024. Established devices like Abbott’s StarClose and Cordis’ ExoSeal deliver reproducible hemostasis for PCI and diagnostic angiography, sustaining demand despite radial penetration. However, radial adoption has already carved share from low-sheath femoral cases and generated a parallel radial compression market.

Large-bore femoral access ≥12 Fr is expanding at 8.12% CAGR on the back of TAVR, EVAR, and mechanical circulatory support. Teleflex’s MANTA and the InSeal patch close 10-25 Fr arteriotomies in a single step, eradicating surgical cut-downs while meeting stringent bleed-through criteria in anticoagulated elders. Radial access maintains utility for diagnostic studies but yields limited incremental revenue to the vascular closure devices market because inexpensive compression bands suffice.

By Procedure Type: Neurovascular Momentum Overtakes Cardiology

Interventional cardiology held 38.54% share of the vascular closure devices market size in 2024. Chronic total occlusion PCI, left main stenting, and alcohol septal ablation supply sustained volume, though radial access curtails femoral device usage. Growth within cardiology hinges on structural heart therapies such as left atrial appendage occlusion, which continue to require femoral access and favor large-bore solutions.

Neurovascular intervention is the fastest-growing slice at 9.43% CAGR. Mechanical thrombectomy volumes are surging because earlier stroke detection meets guideline support for endovascular clot retrieval. The Tubridge flow diverter delivered 100% deployment success in Chinese multicenter assessment, validating procedure efficacy and elevating closure demand. Vascular access for neuro work typically involves 6-9 Fr femoral sheaths, a sweet spot for both active and passive approximators. Electrophysiology ablation adds another vector, where venous closure devices cut bed rest from six hours to two, enhancing patient satisfaction.

Note: Segment shares of all individual segments available upon report purchase

By End User: Outpatient Centers Capture Runway for Expansion

Hospitals continued as the principal customer group with 55.78% of vascular closure devices market share in 2024. They benefit from 24/7 imaging, surgical backup, and volume agreements that incentivize bundled procurement. Tertiary centers increasingly push routine elective cases to satellites or ambulatory hubs to preserve ICU resources for complex care.

Catheterization laboratories and outpatient vascular centers will grow 9.54% per year as payers reimburse same-day discharge and patients value rapid turnover. CMS has introduced additional C-codes recognizing complexity adjustments, directly rewarding facilities that achieve prompt hemostasis and early mobilization[3]. Telemetry‐ready recovery bays, fixed-cost service lines, and lean nursing ratios make ASCs ideal arenas for devices that guarantee predictable closure, uplifting the vascular closure devices market.

Geography Analysis

North America, with 42.67% share, remains the largest regional constituent of the vascular closure devices market. High per-capita procedure rates, early technology adoption, and robust reimbursement frameworks underpin leadership. The FDA granted 510(k) clearance for Cordis’ MYNX CONTROL venous VCD in 2024, emphasizing the region’s role as a primary gateway for next-generation systems. Notwithstanding recalls, North America maintains physician confidence through structured training and rapid post-market surveillance.

Asia-Pacific records the fastest 7.84% CAGR through 2030, spurred by health infrastructure build-out, government investment in cardiovascular care, and an aging population predisposed to stenotic and valvular disease. China’s National Medical Products Administration accepted 61 innovative device dossiers in 2023, signaling accelerating regulatory throughput for local and foreign suppliers^{[3]“NMPA Annual Report on Innovative Devices 2023,” Hankun Law, hankunlaw.com}. Terumo’s double-digit cardiovascular revenue growth and MicroPort CardioFlow’s VitaFlow Liberty TAVI approval in early 2025 confirm vibrant regional demand. Although device cost sensitivity persists, expanding private insurance and public funding improve affordability.

Europe maintains steady, albeit slower, expansion amid transition to the Medical Device Regulation framework. CE marks awarded to Terumo’s Angio-Seal VIP and Vivasure’s PerQseal Elite under MDR attest to adaptability of manufacturers. Radial penetration in continental centers is higher than in North America, moderating femoral closure volumes, yet growth in large-bore structural heart programs counterbalances attrition. Economic pressures in Southern Europe constrain premium device uptake, but Northern European networks compensate with procedure innovation, sustaining the vascular closure devices market.